ProfileGDS5678 / 1419261_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 41% 38% 41% 40% 37% 38% 41% 38% 53% 40% 48% 39% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0484543
GSM967853U87-EV human glioblastoma xenograft - Control 22.9420741
GSM967854U87-EV human glioblastoma xenograft - Control 32.867738
GSM967855U87-EV human glioblastoma xenograft - Control 42.8825841
GSM967856U87-EV human glioblastoma xenograft - Control 52.8722140
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9331137
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9198538
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9253341
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8567538
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2960253
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.908340
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1092848
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8883739
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0899547